Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, develops and markets genetic engineering drugs in the People’s Republic of China and internationally. More Details
High growth potential with excellent balance sheet and pays a dividend.
Share Price & News
How has Beijing SL Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 002038 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 002038's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 002038 underperformed the CN Biotechs industry which returned 39.3% over the past year.
Return vs Market: 002038 underperformed the CN Market which returned 28.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Beijing SL Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Beijing SL Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 002038 (CN¥10.15) is trading above our estimate of fair value (CN¥6.25)
Significantly Below Fair Value: 002038 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 002038 is good value based on its PE Ratio (29.3x) compared to the CN Biotechs industry average (55.8x).
PE vs Market: 002038 is good value based on its PE Ratio (29.3x) compared to the CN market (33.9x).
Price to Earnings Growth Ratio
PEG Ratio: 002038 is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: 002038 is good value based on its PB Ratio (2.1x) compared to the CN Biotechs industry average (6x).
How is Beijing SL Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002038's forecast earnings growth (35.3% per year) is above the savings rate (3.3%).
Earnings vs Market: 002038's earnings (35.3% per year) are forecast to grow faster than the CN market (23.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 002038's revenue (44.5% per year) is forecast to grow faster than the CN market (17.9% per year).
High Growth Revenue: 002038's revenue (44.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002038's Return on Equity is forecast to be low in 3 years time (12.7%).
How has Beijing SL Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 002038 has high quality earnings.
Growing Profit Margin: 002038's current net profit margins (31.8%) are higher than last year (23.9%).
Past Earnings Growth Analysis
Earnings Trend: 002038's earnings have declined by 5% per year over the past 5 years.
Accelerating Growth: 002038's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002038 had negative earnings growth (-26.5%) over the past year, making it difficult to compare to the Biotechs industry average (16.3%).
Return on Equity
High ROE: 002038's Return on Equity (7.2%) is considered low.
How is Beijing SL Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 002038's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥312.2M).
Long Term Liabilities: 002038's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥86.8M).
Debt to Equity History and Analysis
Debt Level: 002038's debt to equity ratio (0.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 002038's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 002038's debt is well covered by operating cash flow (7025.1%).
Interest Coverage: 002038 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Beijing SL Pharmaceutical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 002038's dividend (1.97%) is higher than the bottom 25% of dividend payers in the CN market (0.43%).
High Dividend: 002038's dividend (1.97%) is in the top 25% of dividend payers in the CN market (1.81%)
Stability and Growth of Payments
Stable Dividend: 002038's dividend payments have been volatile in the past 10 years.
Growing Dividend: 002038's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (57.7%), 002038's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mingbo Xu (56 yo)
Dr. Ming Bo Xu founded Beijing SL Pharmaceutical Co., Ltd. in December 1994 and serves as its Chairman, Chief Executive Officer, President and General Manager.
Experienced Board: 002038's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Beijing SL Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Beijing SL Pharmaceutical Co., Ltd.
- Ticker: 2038
- Exchange: SZSE
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥10.428b
- Shares outstanding: 1.03b
- Website: https://www.slpharm.com.cn
Number of Employees
- Beijing SL Pharmaceutical Co., Ltd.
- No. 1 Building, Bitongyuan
- No. 69 Fu shi Road
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, develops and markets genetic engineering drugs in the People’s Republic of China and internationally. The company primarily provides its pr...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 09:12|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.